Company shares are trading at $2.30 significantly higher than the 50 day moving average of $1.59 and quite a bit above the 200 day moving average of $1.60. The 50 day moving average was up $0.71 and the 200 day average went up $0.70 or +43.75%. Trading was heavy with 2,124K shares changing hands in the last trading session. Trading volume was up 661.99% over the stocks average daily volume.
Short traders are feeling a little more bearish on Infinity Pharmaceuticals, Inc. lately if you take a look at the uptick in short interest. The company recorded a rise in short interest from September 15, 2017 to September 29, 2017 of 12.07%. Short shares increased 87,992 over that timeframe. With short interest at 817,013 and short average daily volume at 1,113,430, the short-interest ratio is 1.0 and the percentage of shorted shares is 0.02% as of September 29.
Additionally, here are a few investment firms who have increased or decreased their stake in (INFI). Kcg Holdings, Inc. augmented its investment by buying 47,181 shares an increase of 345.3% from 03/31/2017 to 06/30/2017. Kcg Holdings, Inc. currently owns 60,844 shares with a value of $96,000. The total value of its holdings increased 118.2%. As of the end of the quarter Ubs Group Ag had sold 200 shares trimming its position 40.0%. The value of the investment in Infinity Pharmaceuticals, Inc. decreased from $2,000 to $0 decreasing 100.0% for the reporting period.
As of quarter end Acadian Asset Management LLC had disposed of a total of 155,292 shares trimming its stake by 80.8%. The value of the company’s investment in Infinity Pharmaceuticals, Inc. went from $301,000 to $49,000 a change of $252,000 since the last quarter. As of quarter end Meeder Asset Management Inc had bought a total of 1,448 shares growing its holdings by 121.7%. The value of the investment in (INFI) increased from $2,000 to $4,000 a change of 100.0% quarter to quarter.
As of the last earnings report the EPS was $-1.39 and is estimated to be $-0.92 for the current year with 50,689,000 shares outstanding. Next quarter’s EPS is forecasted at $-0.20 with next year’s EPS anticipated to be $-1.50.
Infinity Pharmaceuticals, Inc., launched on May 11, 2000, is a biopharmaceutical company. The Company is involved in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology..